白云山：公司始终以研发创新作为重点发展战略之一

Group 1 - The core viewpoint of the article is that the company, Baiyunshan, emphasizes research and development innovation as a key part of its growth strategy [1] - The company is currently developing over ten innovative Class 1 drugs, indicating a strong focus on new product development [1] - The disclosed ongoing projects include selective RET small molecule inhibitor BYS10 tablets, BYS30 granules for knee osteoarthritis, Yangyin Shugan granules, LBZ-18, and LBZ-18 oral emulsion [1]